Joss R, Rohrbach D, Pirovino M, Bischoff A, Kiser J, Brunner K
Institut für Medizinische Onkologie der Universität, Bern.
Schweiz Med Wochenschr. 1987 Dec 26;117(52):2113-7.
The antiemetic efficacy of a combination of high-dose metoclopramide, methylprednisolone and flunitrazepam was tested in an open pilot study in 30 tumor patients undergoing strongly emetic chemotherapy. 26 of 30 patients (87%) were partially or completely protected from nausea and vomiting. In 11 of 12 patients receiving the strongly emetogenic cytostatic agent cisplatin in a dose of greater than or equal to 50 mg/m2, the gastrointestinal side effects were partially or completely abolished. The antiemetic efficacy of the combination was maintained during subsequent courses of chemotherapy. All patients experienced somnolence after administration of flunitrazepam. Only 2 of 30 patients had a shortlived extrapyramidal reaction. The combination of high-dose metoclopramide, methylprednisolone and flunitrazepam is an effective antiemetic treatment and should be considered as first-line antiemetic treatment in patients receiving strongly emetic cancer chemotherapy.
在一项开放性试验研究中，对30名接受强致吐性化疗的肿瘤患者，测试了大剂量胃复安、甲基强的松龙和氟硝西泮联合使用的止吐效果。30名患者中有26名（87%）在一定程度上或完全免受恶心和呕吐困扰。在12名接受剂量大于或等于50mg/m²的强致吐性细胞抑制剂顺铂治疗的患者中，有11名患者的胃肠道副作用在一定程度上或完全消除。在后续化疗疗程中，该联合用药的止吐效果得以维持。所有患者在使用氟硝西泮后均出现嗜睡。30名患者中只有2名出现短暂的锥体外系反应。大剂量胃复安、甲基强的松龙和氟硝西泮联合使用是一种有效的止吐治疗方法，对于接受强致吐性癌症化疗的患者，应考虑将其作为一线止吐治疗方案。
